Apoptosis in Young Rats with Adriamycin-Induced Cardiomyopathy—Comparison with Pirarubicin, a New Anthracycline Derivative

Koh, Eikan; Ueda, Yosimichi; Nakamura, Tsuneyuki; Kobayashi, Azusa; Katsuta, Shogo; Takahashi, Hiroaki

doi:10.1203/00006450-200202000-00021

Cited by 32 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To prevent anthracycline-induced cardiotoxicity, cardioprotective agents such as dexazoxane, 16 probucol 28 and anti-Fas ligand antibody 6 have been used clinically or experimentally; however, all have limitations. Beta-blockers, especially carvedilol and angiotensin-converting enzyme inhibitors, which have cardioprotective effects, have been shown to be clinically effective for patients with chronic heart failure, including DCM.…”

Section: Circulation Journal Vol68 February 2004mentioning

confidence: 99%

Troponin-T and Brain Natriuretic Peptide as Predictors for Adriamycin-Induced Cardiomyopathy in Rats

Koh

Nakamura

Takahashi

2004

Circ J

Self Cite

View full text Add to dashboard Cite

Section: Circulation Journal Vol68 February 2004mentioning

confidence: 99%

Troponin-T and Brain Natriuretic Peptide as Predictors for Adriamycin-Induced Cardiomyopathy in Rats

Koh

Nakamura

Takahashi

2004

Circ J

Self Cite

View full text Add to dashboard Cite

“…Pirarubicin (tetrahydropyranyl adriamycin, THP), another anthracycline derivative [11], was introduced for the treatment of NHL in 1979, in part to provide an effective alternative with less cardiotoxicity. Several studies reported the superiority of pirarubicin over DOX, with a higher CR rate [9] and less cardiotoxicity [12][13][14], but most studies were small scale with a limited follow-up period. Since both THP-COP and CHOP regimens have been used extensively in China for decades, their efficacy and safety could be retrospectively compared in a large number of cases and over a long follow-up period in aggressive NHL.…”

Section: Introductionmentioning

confidence: 99%

Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin’s lymphoma: single center, 15-year experience

et al. 2009

View full text Add to dashboard Cite

Pirarubicin is an analog of doxorubicin. Few studies have compared the long-term outcomes of patients receiving pirarubicin-based THP-COP and doxorubicin-based CHOP in the treatment of non-Hodgkin's lymphoma (NHL). We retrospectively compared the efficacy and safety of these two regimens in 459 previously untreated aggressive NHL patients admitted to Sun Yat-Sen University Cancer Center from 1987 to 2003. For initial treatment, 205 patients received the THP-COP regimen, and 254 patients received the CHOP regimen. The patients' characteristics were well balanced. The groups did not differ in the complete remission rate (THP-COP, 57.1% vs. CHOP, 57.0%; P = 0.998) or response rate (THP-COP, 82.9% vs. CHOP, 81.5%; P = 0.691). At a median follow-up of 95.7 months, the 8-year survival rates were also similar (overall survival: THP-COP, 55.8% vs. CHOP, 56.7%; progression-free survival: THP-COP, 47.3% vs. CHOP, 43.5%; lymphoma-specific survival: THP-COP, 51.2% vs. CHOP, 48.5%). The THP-COP group had fewer cases of alopecia (P < 0.001) and gastrointestinal toxicities (P = 0.015). A tendency toward decreased arrhythmia (P = 0.075), especially in elderly patients (P = 0.030), was found. In combination chemotherapy for aggressive NHL, pirarubicin has comparable efficacy to doxorubicin and has a lower incidence of alopecia, gastrointestinal toxicities, and arrhythmia. Further studies are warranted to confirm these results.

show abstract

“…Doxorubicin (Dox) is a widely used anti-tumor agent. However, systemic treatment with Dox is complicated by its dose limiting toxicity, even at relatively low concentrations, as well as its rapid plasma clearance and distribution to nonrelevant tissues [5][6][7][8][9][10] . Pegylated liposomal doxorubicin (PLD) not only increases concentration of Dox in tumor and thus enhances its antitumor activity, but also has lower toxicity to the cardiac muscle compared with Dox alone [7,[11][12][13][14][15] .…”

Section: Introductionmentioning

confidence: 99%

Effect of O-4-ethoxyl-butyl-berbamine in combination with pegylated liposomal doxorubicin on advanced hepatoma in mice

Fang¹,

Yu²,

Yang³

et al. 2004

WJG

View full text Add to dashboard Cite

AIM: To study the synergistic effects of calmodulin (CaM) antagonist O-4-ethoxyl-butyl-berbamine (EBB) and pegylated liposomal doxorubicin (PLD) on hepatoma-22 (H 22 ) in vivo. METHODS:Hepatoma model was established in 50 Balb/c mice by inoculating H 22 cells (2.5×10 6 ) subcutaneously into the right backs of the mice. These mice were divided into 5 groups, and treated with saline only, PLD only, doxorubicin (Dox) only, PLD plus EBB and Dox plus EBB, respectively. In the treatment groups, mice were given 5 intravenous of PLD or Dox on days 0, 3, 6, 9 and 12. The first dosage of PLD or Dox was 4.5 mg/kg, the other 4 injections was 1 mg/kg. EBB (5 mg/kg) was coadministered with PLD or Dox in the corresponding groups. The effect of drugs on the life spans of hepatoma-bearing mice and tumor response to the drugs were recorded. Dox levels in the hepatoma cells were measured by a fluorescence assay. Light microscopy was performed to determine the histopathological changes in the major organs of these tumor-bearing mice.

show abstract

Apoptosis in Young Rats with Adriamycin-Induced Cardiomyopathy—Comparison with Pirarubicin, a New Anthracycline Derivative

Cited by 32 publications

References 11 publications

Troponin-T and Brain Natriuretic Peptide as Predictors for Adriamycin-Induced Cardiomyopathy in Rats

Troponin-T and Brain Natriuretic Peptide as Predictors for Adriamycin-Induced Cardiomyopathy in Rats

Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin’s lymphoma: single center, 15-year experience

Effect of O-4-ethoxyl-butyl-berbamine in combination with pegylated liposomal doxorubicin on advanced hepatoma in mice

Contact Info

Product

Resources

About